Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 446 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Cómo mi diagnóstico de cáncer a los 17 años cambió mi... December 14, 2020 Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs August 12, 2022 EMA Recommends Extension of Therapeutic Indications for Tremelimumab July 20, 2023 Shelter Puppies Got A Private Tour Of The Georgia Aquarium March 31, 2020 Load more HOT NEWS Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures... Heine H. Hansen Award: Johan Vansteenkiste and Fiona Blackhall Honoured for... FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma
